Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI. Shaw AT, et al. Among authors: chiari r. Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25. Lancet Oncol. 2019. PMID: 31669155 Clinical Trial.
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L. Ludovini V, et al. Among authors: chiari r. J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b. J Thorac Oncol. 2011. PMID: 21258250 Free article.
Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation.
Metro G, Chiari R, Mare M, Giannarelli D, Tofanetti FR, Minotti V, Ferraldeschi M, Giuffrida D, Marcomigni L, Bennati C, Fischer MJ, Meacci M, Bellavita R, Pistola L, Ludovini V, Crinò L. Metro G, et al. Among authors: chiari r. Cancer Chemother Pharmacol. 2011 Dec;68(6):1405-12. doi: 10.1007/s00280-011-1632-x. Epub 2011 Apr 6. Cancer Chemother Pharmacol. 2011. PMID: 21468755
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, Garavaglia D, Tofanetti FR, Flacco A, Siggillino A, Baldelli E, Tonato M, Crinò L. Ludovini V, et al. Among authors: chiari r. J Thorac Oncol. 2011 Dec;6(12):2018-26. doi: 10.1097/JTO.0b013e3182307e1f. J Thorac Oncol. 2011. PMID: 22052224 Free article.
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, Bellezza G, Tofanetti FR, Siggillino A, Baldelli E, Flacco A, Giuffrida D, Sidoni A, Crinò L. Ludovini V, et al. Among authors: chiari r. Cancer Chemother Pharmacol. 2012 May;69(5):1289-99. doi: 10.1007/s00280-012-1829-7. Cancer Chemother Pharmacol. 2012. PMID: 22302407
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
Metro G, Chiari R, Duranti S, Siggillino A, Fischer MJ, Giannarelli D, Ludovini V, Bennati C, Marcomigni L, Baldi A, Giansanti M, Minotti V, Crinò L. Metro G, et al. Among authors: chiari r. Lung Cancer. 2012 Oct;78(1):81-6. doi: 10.1016/j.lungcan.2012.06.005. Epub 2012 Jul 4. Lung Cancer. 2012. PMID: 22770374
Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L. Metro G, et al. Among authors: chiari r. Clin Lung Cancer. 2014 Jan;15(1):86-92. doi: 10.1016/j.cllc.2013.08.002. Epub 2013 Oct 17. Clin Lung Cancer. 2014. PMID: 24139827
Future options for ALK-positive non-small cell lung cancer.
Iacono D, Chiari R, Metro G, Bennati C, Bellezza G, Cenci M, Ricciuti B, Sidoni A, Baglivo S, Minotti V, Crinò L. Iacono D, et al. Among authors: chiari r. Lung Cancer. 2015 Mar;87(3):211-9. doi: 10.1016/j.lungcan.2014.12.017. Epub 2015 Jan 3. Lung Cancer. 2015. PMID: 25601484 Review.
209 results